Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clevidipine Butyrate for Hypertensive Emergency
NCT05044364Phase 3Unknown
- Sponsor
- Shenzhen People's Hospital
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of clevidipine in hypertensive emergency and hypertensive urgency (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoint: Percentage of patients whose systolic blood pressure dropped to the target range at 30 minutes. Status: unknown.
02
Drugs
clevidipine
03
Conditions
hypertensive emergencyhypertensive urgency
Beyond the preview
Go deeper on NCT05044364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05044364.